TT-702 in Patients With Advanced Solid Tumours.

Summary

This clinical trial is evaluating the drug candidate TT-702 in patients with advanced solid tumours. The main aims of the trial are to determine the maximum dose of TT-702 that can be given safely to patients alone and in combination with other anti-cancer agents.

Timeline

Start

2022-01-19

Primary completion

2027-06

Completion

2027-06

Publications

• Whitaker D, Francis L, Karaborni S, Smith S, Craigen JL, Svetlik S, Barnett S, Veal GJ. Development and validation of an LC-MS/MS method for the quantification of novel therapeutic TT-478, a selective adenosine receptor 2B antagonist, for a phase I/II clinical trial. Bioanalysis. 2025 Sep;17(17):1105-1112. doi: 10.1080/17576180.2025.2554564. Epub 2025 Oct 17.

Drugs

Indications